DUBLIN, May 19, 2016 /PRNewswire/ -- Allergan plc (NYSE:
AGN) a leading global pharmaceutical company, today announced that
Brent Saunders, Allergan's CEO and
President, will be featured in a fireside chat session at the
Bernstein 32nd Annual Strategic Decisions Conference on
Thursday, June 2, 2016 at
4:00 p.m. ET at the Waldorf Astoria
Hotel in New York, NY.
Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO
The presentation will be webcast live and can be accessed on
Allergan's Investor Relations web site at
http://ir.allergan.com. The webcast can also be accessed
through the following URL:
https://cc.talkpoint.com/bern001/060116a_ae/?entity=54_D1QC6MV
An archived version will be available approximately one hour
after the live presentation ends and can be accessed at the same
locations for 180 days.
About Allergan
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global
pharmaceutical company and a leader in a new industry model –
Growth Pharma. Allergan is focused on developing,
manufacturing and commercializing innovative branded
pharmaceuticals, high-quality generic and over-the-counter
medicines and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that
provide valuable treatments for the central nervous system, eye
care, medical aesthetics, gastroenterology, women's health,
urology, cardiovascular and anti-infective therapeutic categories,
and operates the world's third-largest global generics business,
providing patients around the globe with increased access to
affordable, high-quality medicines. Allergan is an industry leader
in research and development, with one of the broadest development
pipelines in the pharmaceutical industry and a leading position in
the submission of generic product applications globally.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives.
For more information, visit Allergan's website at
www.allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective of existing trends and
information as of the date of this release. Except as expressly
required by law, Allergan disclaims any intent or obligation to
update these forward-looking statements. Actual results may differ
materially from Allergan's current expectations depending upon a
number of factors affecting Allergan's business. These factors
include, among others, the difficulty of predicting the timing or
outcome of FDA approvals or actions, if any; the impact of
competitive products and pricing; market acceptance of and
continued demand for Allergan's products; difficulties or delays in
manufacturing; and other risks and uncertainties detailed in
Allergan's periodic public filings with the Securities and Exchange
Commission, including but not limited to Allergan's Quarterly
Report on Form 10-Q for the quarter ended March 31, 2016 (such periodic public filings
having been filed under the "Actavis plc" name). Except as
expressly required by law, Allergan disclaims any intent or
obligation to update these forward-looking statements.
CONTACTS:
Allergan:
Investors:
Lisa DeFrancesco
(862) 261-7152
Media:
Mark Marmur
(862) 261-7558
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/allergan-to-present-at-the-bernstein-32nd-annual-strategic-decisions-conference-300271222.html
SOURCE Allergan plc